Carboprost tromethamine is a synthetic form of the hormone prostaglandin F2α, which has been used in medical practice for over four decades now. It is commonly used to induce labor, control postpartum hemorrhage and terminate pregnancy, among other uses. This article will discuss carboprost tromethamine in detail, with an emphasis on the various uses and dosages for medical professionals. In addition, it will provide information on safety concerns and potential side effects that healthcare professionals should be aware of when administering this medication to their patients.
Carboprost tromethamine is a synthetic prostaglandin analogue used to induce labor and control postpartum hemorrhage. It is sold under the brand names Hemabate and Methergine. Carboprost tromethamine has a similar structure to natural prostaglandins, which are hormones that play an important role in regulating many bodily functions, including labor and delivery. When given as an injection, carboprost tromethamine works by stimulating contractions of the uterus and increasing the production of oxytocin, a hormone that helps control bleeding after childbirth. Carboprost tromethamine is typically only used when other methods of induction or control of postpartum hemorrhage have failed.
Carboprost tromethamine is indicated for the medical termination of pregnancy through 63 days gestational age. It can also be used to control postpartum hemorrhage when uterine contractions are inadequate. Common side effects of carboprost tromethamine include nausea, vomiting, diarrhea, abdominal pain and fever.
Carboprost tromethamine (Hemabate) is a prostaglandin F2-alpha analogue used to treat postpartum hemorrhage (PPH) due to uterine atony. It is administered as an intramuscular injection. The recommended dose of carboprost tromethamine for the treatment of PPH is 0.25 mg/kg administered intramuscularly every 15 minutes for two doses, followed by 0.5 mg/kg every 30 minutes for four doses, and then 1 mg/kg every 60 minutes as needed. The maximum recommended dose is 30 mg per day. For the prevention of PPH, the recommended dose of carboprost tromethamine is 0.5 mg/kg administered intramuscularly immediately after delivery of the placenta.
Carboprost tromethamine is a medication used to help induce labor or to control bleeding after childbirth or abortion. It is a synthetic version of the hormone prostaglandin F2α. Carboprost tromethamine should only be used under the supervision of a medical professional. Carboprost tromethamine should only be used under the supervision of a medical professional. It is not intended for use by pregnant women without medical supervision. This medication can cause uterine contractions. This medication can also cause side effects such as nausea, vomiting, diarrhea, abdominal pain and headache.
Carboprost tromethamine (Hemabate) is a synthetic prostaglandin used to induce labor or terminate pregnancy. It can also be used to control postpartum bleeding. Carboprost tromethamine works by causing the uterus to contract. Common side effects of carboprost tromethamine include nausea, vomiting, diarrhea, headache and dizziness. This medication may also cause uterine rupture and other serious side effects in pregnant women.
Drug interactions may occur with carboprost tromethamine. The most common drug interactions include: Nonsteroidal anti-inflammatory drugs (NSAIDs), Anticoagulants (blood thinners), Aspirin, Barbiturates, Corticosteroids, Diuretics (water pills), estrogens, lithium
Carboprost Tromethamine is an important medication used to treat several medical conditions. As a medical professional, it is essential that you understand the uses, dosages and other aspects of using this drug correctly. We hope this article has provided all of the necessary information for safely administering Carboprost Tromethamine so that you can ensure your patients are receiving the best care possible.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
2.
Formaldehyde releasers found in common personal care products used especially by Black and Latina women
3.
Personalized Breast Cancer Treatment; Insights Into HPV in Men; Exercise and Cancer
4.
'Ticking Time Bomb'; Jimmy Carter's Lasting Impact on Cancer; Breast Cancer-CVD Link
5.
GLP-1 Receptor antagonists used in a study allay fears about thyroid cancer.
1.
Biomimetic Nanovesicles Target Senescent-Escape Cancer Stem Cells in Breast Cancer
2.
Exploring the Mysteries of Myxoma: A New Frontier in Medical Research
3.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
4.
Unraveling the Mystery of Non-Caseating Granulomas: A Comprehensive Guide
5.
Chemotherapy Advances: Albumin I.V., Trastuzumab, Liposomal Doxorubicin & More
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
2.
Navigating the Complexities of Ph Negative ALL - Part X
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Important Points to Know
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation